1. Celecoxib and the CLASS trial: data massaging by industry. Prescrire International. 2002; 11: 190–1.

2. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-infl ammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284: 1247–55.

3. Okie S. Missing data on Celebrex. Washington Post. 2001 Aug 5.

4. Lichtenstein D.R., Wolfe M.M. COX-2-Selective NSAIDs: new and improved? JAMA. 2000; 284: 1297–9.

5. Jüni P., Rutjes A.W., Dieppe P.A. Are selective COX-2 inhibitors superior to traditional non steroidal anti-infl ammatory drugs? BMJ. 2002; 324: 1287–8.

6. Thomas K. In documents on pain drug Celebrex, signs of doubt and deception. New York Times. 2012 June 24.

7. Lu H.L. Statistical Reviewer Briefing Document for the Advisory Committee. FDA. 2000; NDA20-998.

8. FDA. Summary minutes, AAC & DSaRM. 2005 Feb 16–18. Available online at: www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4090M1: Final.htm (accessed February 2005).

9. Deeks J.J., Smith L.A., Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ. 2002; 325: 619.

10. Deeks J.J., Smith L.A., Bradley M.D. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. BMJ. 2003; 326: 335–6.

11. Geis G.S. Pharmacia’s response to editorial. BMJ. 2002; 325: 161–2.

12. Jüni P., Rutjes A.W.S, Dieppe P. Authors’ reply. BMJ. 2002; 325: 163–4.

13. Hrachovec J.B., Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001; 286: 2398.

14. White W.B., Faich G., Whelton A., et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002; 89: 425–30.

15. Andrade M. In clear sight. BMJ. 2009; 339: 538–40.

16. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071–80.

17. Caldwell B., Aldington S., Weatherall M., et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99: 132–40.

18. Crone M. [Pfizer gets additional fine for illegal marketing]. Berlingske. 2004 Nov 16.

19. Gøtzsche P.C. [COX-2 inhibitors and other nonsteroidal, anti-infl ammatory drugs – what future?] Ugeskr Læger. 2006; 168: 1972–3.

20. DeAngelis C.D., Thornton J.P. Preserving confidentiality in the peer review process. JAMA. 2008; 299: 1956.

21. Dyer C. Pfizer asks journal for comments made by peer reviewers. BMJ. 2008; 336: 575.

22. Feeley J., Van Voris B. Pfizer destroyed arthritis drugs’ files, investors claim. Bloomberg. 2012 Nov 21. Available online at: www.bloomberg.com/news/2012-11-21/pfi zer-destroyed-arthritisdrugs-files-investors-claim.html (accessed 10 July 2013).

23. Mamdani M., Juurlink D.N., Kopp A., et al. Gastrointestinal bleeding after the introduction of COX-2 inhibitors: ecological study. BMJ. 2004; 328: 1415–6.

24. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001; 345: 433–42.

25. Abramson J. Overdo$ed America. New York: HarperCollins; 2004.

26. Blower A.L., Brooks A., Fenn G.C., et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther. 1997; 11: 283–91.

27. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.

28. Gibson L. Drug company sues Spanish bulletin over fraud claim. BMJ. 2004; 328: 188.

29. Laporte J.-R. Merck Sharpe and Dohme versus Laporte. Lancet. 2004; 364: 416.

30. Honig P. Merck Sharp and Dohme versus Laporte. Lancet. 2004; 363:1079–80.